An Australian pharmaceutical company has identified Sardinia as an ideal place to grow medical cannabis for international markets. The company’s directors are looking for organizations with adequate resources for cultivation for subsequent export to Australia and New Zealand. Medical Organic Cannabis Australia (MOCA) is pioneering the market as the country’s first medical organic cannabis company.
Medical Organic Cannabis Australia (MOCA) is a private company, based in Sydney, Australia. They are now researching medical cannabis in Sardinia and have identified several fertile regions as the most favorable options.
The company is the first medical organic cannabis company in Australia that successfully submitted an offer to provide the Italian Ministry of Defence with an annual share of medical cannabis at the beginning of this year.
In order to find more on this subject, one potentially useful cannabis news tool is the Hemp.im app. You can find more information about cannabis markets and other important news in the cannabis sector in the Hemp.im app.
Cannabis in Sardinia will benefit the global medical cannabis market
The directors of the company, Cav. Alessandro Sorbello and Dr. Emanuela Ispani, have been in Italy since May working with the Italian regions to determine the most suitable environmental conditions for the cultivation of cannabis in Sardinia
The directors met with officials in Tuscany, Abruzzo, Piedmont, Lombardy, Campania, and Sicily.
The global medical cannabis market is growing exponentially and the anticipated demand for CBD (a component of medical cannabis) will grow by more than 700% in 2020.
Global spending on legal cannabis worldwide will reach $57 billion in a decade, according to Arcview Market Research and BDS Analytics.
Thanks to the push of cannabis legalization and growing demand, revenue generated by cannabis in the U. S. is expected to reach $23.4 billion by 2022.
Medical cannabis in Sardinia to aid chronic diseases
MOCA holds pharmaceutical licenses granted by the Australian federal government for the import and wholesale trade of medical products. This includes cannabis for supplying hospitals and specialist clinics.
MOCA’s cannabis-based medicines are used to treat conditions such as childhood epilepsy, Parkinson’s disease, muscle spasms caused by multiple sclerosis, nausea caused by cancer chemotherapy and poor appetite and weight loss caused by chronic diseases such as HIV.
It will progressively focus on the cultivation of over 300 hectares of cannabis in Sardinia.
The pharmaceutical company also has proprietary protocols for the cultivation of medical cannabis and plant genetics, developed in collaboration with its research group and approved by Australian, New Zealand, and Canadian governments.
Establishing a market for medical cannabis in Sardinia
During their stay in Sardinia, the directors of MOCA have established a collaborative relationship with the University of Cagliari in order to assist the development activities of the sector in the region.
The company has a policy of guaranteed repurchase of the inflorescences and biomass produced with its growers and pays well above industry standards.
The contracts for the cultivation and purchase of the produced biomass will see a redistribution of about $22 million (€20 million) per year in the region for the next 10 years.
Once the appropriate solutions are confirmed, the directors of MOCA will return at the beginning of 2020 to develop the project bringing with them their team of experts from Australia, Canada, and the U.S.
The cultivation will enable MOCA to supply pharmaceutical-grade cannabis to international markets. Cultivation is expected to start in the first quarter of 2020.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in La Provincia del Sulcis Iglesiente, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.